A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (monarcHER)
The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant or chemotherapy in women with HR+, HER2+ locally advanced or metastatic breast cancer after prior exposure to at least two HER2-directed therapies for advanced disease.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have a diagnosis of HR+, HER2+ advanced breast cancer
Participant must have unresectable, locally advanced, recurrent breast cancer or metastatic breast cancer
Participant must provide adequate tumor tissue prior to participation
Participant must have previously received at least two HER2-directed therapies for advanced disease
Participant must have received a taxane and trastuzumab emtansine (T-DM1) in any disease setting
Participant must have received any endocrine therapy (excluding fulvestrant)
Participant must have postmenopausal status
Participants Must Not:
Participant must not have received prior treatment with any cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor
Participant must not have had symptomatic congestive heart failure, heart attack, or unstable angina within the last 6 months
Participant must not have known central nervous system (CNS) metastases that are untreated, symptomatic, or require steroids to control symptoms
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo